stockrowFortrea Holdings Inc.
FTRE Healthcare Biotechnology
Fortrea Holdings Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.7 billion, up 1.00% from fiscal 2024.
- Revenue
- −1.40%
- EPS
- +103.7%
- Free cash flow
- −34.0%
- Total debt
- −6.33%
Quarter to September 2026, against a year earlier
Follow FTRE
Alert me
Fortrea Holdings Inc. (FTRE) Shares outstanding
Fortrea Holdings Inc.'s shares outstanding at the end of fiscal 2025 was $91.2M, unchanged from fiscal 2024. At the end of the quarter to 30 September 2026 it was $101.2M. Over the past ten years it has ranged from $88.8M (fiscal 2023) to $91.2M (fiscal 2025) — the current reading is the highest in ten years. Fortrea Holdings Inc. ranks 149th of 600 Biotechnology companies by shares outstanding.
Shares outstanding, annual
Embed this chart
Annual newest first
| Period | Shares outstanding | Change |
|---|---|---|
| FY2025 | $91.2M | 1.90% |
| FY2024 | $89.5M | 0.79% |
| FY2023 | $88.8M | 0.00% |
| FY2022 | $88.8M | 0.00% |
| FY2021 | $88.8M | (0.22%) |
| FY2020 | $89.0M | — |
Quarterly newest first
| Period | Shares outstanding | Change |
|---|---|---|
| Sep 2026 | $101.2M | 6.75% |
| Jun 2026 | $94.8M | 1.28% |
| Mar 2026 | $93.6M | 2.63% |
| Dec 2025 | $91.2M | 0.00% |
| 13 more quarters | Free account |
Against its own ten years
Shares outstanding against peers
| Company | Shares outstanding |
|---|---|
| VIR Vir Biotechnology, Inc. compare | $169.3M |
| BHVN Biohaven Ltd. compare | $151.0M |
| IMNM Immunome, Inc. compare | $113.3M |
| SRPT Sarepta Therapeutics, Inc. compare | $105.9M |
| REPL Replimune Group, Inc. compare | $105.2M |
| FTRE Fortrea Holdings Inc. | $101.2M |
| ZYME Zymeworks Inc. compare | $73.0M |
| HRMY Harmony Biosciences Holdings, Inc. compare | $59.7M |
| TRAX First Tracks Biotherapeutics, Inc. compare | $35.7M |
What Shares outstanding is
Shares (Diluted, Weighted) tells an investor how many shares a company’s earnings are spread across once potential new shares are counted.
Reported line item